Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation.
- Author:
Xiao-lian LUO
1
;
Yan WANG
;
Geng-shan TIAN
;
Xi-xian FU
;
Yong-yi WANG
;
Lai WEI
;
Jie CHEN
;
Sheng SU
;
Gong-ren FAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Child; Combined Modality Therapy; DNA, Viral; blood; Dipyridamole; therapeutic use; Hepatitis B Vaccines; therapeutic use; Hepatitis B virus; genetics; isolation & purification; Hepatitis B, Chronic; therapy; virology; Humans; Immunotherapy; Lamivudine; therapeutic use; Levamisole; therapeutic use; Middle Aged; Mutation
- From: Chinese Journal of Experimental and Clinical Virology 2004;18(3):284-286
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the incidence of precore mutation in HBeAg negative HBV infected patients and the therapeutic effect of the immune therapy (levamisole + HBV vaccine + dipyridamole) on patients chronically infected by HBV with precore mutation.
METHODSThe precore region of HBV from the HBeAg (-) chronic hepatitis patients was sequenced and the patients suffered from HBV with precore mutation were treated with immune therapy.
RESULTSThe precore mutation rate was 10/12. The therapeutic effect of the immune therapy on the precore mutation patients (5/7) was better than that on the HBsAg(+), HBeAg(+) patients (2/11), P less than 0.05.
CONCLUSIONThe precore mutation rate was quite high in the HBsAg(+), HBeAg(-) patients we studied. The immune-therapy has some therapeutic effects on the patients with precore mutation. But the number of cases was too small, further study is needed.
